Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT

医学 茶碱 随机对照试验 肺病 吸入性皮质类固醇 慢性阻塞性肺病 哮喘 支气管扩张剂 内科学 重症监护医学 皮质类固醇 物理疗法
作者
Graham Devereux,Seonaidh Cotton,Shona Fielding,Nicola McMeekin,Peter J. Barnes,Andrew Briggs,Graham Burns,Rekha Chaudhuri,Henry Chrystyn,Lisa Davies,Anthony De Soyza,Simon Gompertz,John Haughney,Karen Innes,Joanna Kaniewska,Amanda Lee,Alyn H. Morice,John Norrie,A. Sullivan,Andrew M. Wilson
出处
期刊:Health Technology Assessment [NIHR Journals Library]
卷期号:23 (37): 1-146 被引量:17
标识
DOI:10.3310/hta23370
摘要

Background Despite widespread use of therapies such as inhaled corticosteroids (ICSs), people with chronic obstructive pulmonary disease (COPD) continue to suffer, have reduced life expectancy and utilise considerable NHS resources. Laboratory investigations have demonstrated that at low plasma concentrations (1–5 mg/l) theophylline markedly enhances the anti-inflammatory effects of corticosteroids in COPD. Objective To determine the clinical effectiveness and cost-effectiveness of adding low-dose theophylline to a drug regimen containing ICSs in people with COPD at high risk of exacerbation. Design A multicentre, pragmatic, double-blind, randomised, placebo-controlled clinical trial. Setting The trial was conducted in 121 UK primary and secondary care sites. Participants People with COPD [i.e. who have a forced expiratory volume in 1 second (FEV 1 )/forced vital capacity (FVC) of < 0.7] currently on a drug regimen including ICSs with a history of two or more exacerbations treated with antibiotics and/or oral corticosteroids (OCSs) in the previous year. Interventions Participants were randomised (1 : 1) to receive either low-dose theophylline or placebo for 1 year. The dose of theophylline (200 mg once or twice a day) was determined by ideal body weight and smoking status. Primary outcome The number of participant-reported exacerbations in the 1-year treatment period that were treated with antibiotics and/or OCSs. Results A total of 1578 people were randomised (60% from primary care): 791 to theophylline and 787 to placebo. There were 11 post-randomisation exclusions. Trial medication was prescribed to 1567 participants: 788 in the theophylline arm and 779 in the placebo arm. Participants in the trial arms were well balanced in terms of characteristics. The mean age was 68.4 [standard deviation (SD) 8.4] years, 54% were male, 32% smoked and mean FEV 1 was 51.7% (SD 20.0%) predicted. Primary outcome data were available for 98% of participants: 772 in the theophylline arm and 764 in the placebo arm. There were 1489 person-years of follow-up data. The mean number of exacerbations was 2.24 (SD 1.99) for participants allocated to theophylline and 2.23 (SD 1.97) for participants allocated to placebo [adjusted incidence rate ratio (IRR) 0.99, 95% confidence interval (CI) 0.91 to 1.08]. Low-dose theophylline had no significant effects on lung function (i.e. FEV 1 ), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact. Hospital admissions due to COPD exacerbation were less frequent with low-dose theophylline (adjusted IRR 0.72, 95% CI 0.55 to 0.94). However, 39 of the 51 excess hospital admissions in the placebo group were accounted for by 10 participants having three or more exacerbations. There were no differences in the reporting of theophylline side effects between the theophylline and placebo arms. Limitations A higher than expected percentage of participants (26%) ceased trial medication; this was balanced between the theophylline and placebo arms and mitigated by over-recruitment ( n = 154 additional participants were recruited) and the high rate of follow-up. The limitation of not using documented exacerbations is addressed by evidence that patient recall is highly reliable and the results of a small within-trial validation study. Conclusion For people with COPD at high risk of exacerbation, the addition of low-dose oral theophylline to a drug regimen that includes ICSs confers no overall clinical or health economic benefit. This result was evident from the intention-to-treat and per-protocol analyses. Future work To promote consideration of the findings of this trial in national and international COPD guidelines. Trial registration Current Controlled Trials ISRCTN27066620. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 23, No. 37. See the NIHR Journals Library website for further project information.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Root完成签到,获得积分10
1秒前
1秒前
zq完成签到,获得积分10
1秒前
caicai完成签到,获得积分10
1秒前
Beibei完成签到 ,获得积分10
1秒前
欣喜的曼柔完成签到,获得积分10
2秒前
2秒前
NeymarYt98发布了新的文献求助10
2秒前
乐乐的应助被wenjian采纳,获得10
2秒前
2秒前
陈文海发布了新的文献求助10
2秒前
尘归尘完成签到 ,获得积分10
2秒前
忠嗣院学员完成签到 ,获得积分10
2秒前
2秒前
3秒前
percy完成签到,获得积分10
3秒前
风格和完成签到,获得积分10
3秒前
稳重听双完成签到,获得积分10
3秒前
ERIC发布了新的文献求助10
3秒前
靓靓鱼发布了新的文献求助10
4秒前
眠羊完成签到,获得积分10
4秒前
4秒前
zzz发布了新的文献求助10
4秒前
caicai发布了新的文献求助10
4秒前
爱吃麦当劳完成签到 ,获得积分10
4秒前
浅沫juanjuan完成签到 ,获得积分10
4秒前
easton完成签到,获得积分10
5秒前
zxdw完成签到,获得积分10
5秒前
舒一一完成签到 ,获得积分10
5秒前
科研小啪菜完成签到,获得积分10
5秒前
faust0052完成签到 ,获得积分10
5秒前
L李发布了新的文献求助10
5秒前
人间白首发布了新的文献求助10
5秒前
Hakuna完成签到,获得积分10
5秒前
大模型的应助被大眠羊采纳,获得10
5秒前
张萍发布了新的文献求助10
7秒前
王梦姣发布了新的文献求助10
7秒前
邵大王完成签到,获得积分10
7秒前
guoguo发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180339
求助须知:如何正确求助?哪些是违规求助? 9570391
关于积分的说明 21811279
捐赠科研通 7776418
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479091